EXCELLENT EFFICACY AND SAFETY OF SOFOSBUVIR, GLECAPREVIR, PIBRENTASVIR AND RIBAVIRIN FOR RETREATMENT OF CHRONIC HEPATITIS C AFTER SOFOSBUVIR, VELPATASVIR AND VOXILAPREVIR FAILURE

被引：0
|
作者：
Saxena, Varun [1 ,2 ]
McKinney, Jeff [2 ]
Chamberland, Scott [1 ]
Catalli, Lisa [2 ]
Seo, Suk [1 ]
Ready, Joanna B. [3 ]
Price, Jennifer C. [2 ]
机构：
[1] Kaiser Permanente Northern Calif, Oakland, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Kaiser Permanente Santa Clara Med Ctr, Santa Clara, CA USA
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
98
引用
收藏
页码：66A / 67A
页数：2
相关论文
共 50 条
  • [1] Betrixaban, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir
    Hussar, Daniel A.
    Inman, Bradley
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2017, 57 (06) : 750 - 754
  • [2] Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
    Pearlman, Brian
    Perrys, Michael
    Hinds, Andrew
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (09): : 1550 - 1552
  • [3] Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
    Ruiz-Cobo, Juan Carlos
    Llaneras, Jordi
    Forns, Xavier
    Gallego Moya, Adolfo
    Conde Amiel, Isabel
    Arencibia, Ana
    Diago, Moises
    Garcia-Samaniego, Javier
    Castellote, Jose
    Llerena, Susana
    Rodriguez-Seguel, Elisa
    Mateos, Beatriz
    Rodriguez, Manuel
    Rosales Zabal, Jose Miguel
    Fernandez, Inmaculada
    Calleja, Jose Luis
    Morillas, Rosa Maria
    Montoliu, Silvia
    Andrade, Raul J.
    Badia Aranda, Ester
    Hernandez-Guerra, Manuel
    Mate, Carlota Jimeno
    Gonzalez-Santiago, Jesus M.
    de Cuenca, Beatriz
    Bernal-Monterde, Vanesa
    Delgado, Manuel
    Turnes, Juan
    Lens, Sabela
    Buti, Maria
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (02) : 201 - 211
  • [4] Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
    Ruiz-Cobo, Juan Carlos
    Llaneras, Jordi
    Buti, Maria
    Forns, Xavier
    Conde, Isabel
    Arencibia Almeida, Ana
    Diago, Moises
    Garcia-Samaniego Rey, Francisco Javier
    Castellote Alonso, Jose
    Llerena, Susana
    Rodriguez, Elisa
    Mateos Munoz, Beatriz
    Rodriguez, Manuel
    Fernandez Vazquez, Inmaculada
    Rosales Zabal, Jose Miguel
    Calleja Panero, Jose Luis
    Morillas, Rosa M.
    Montoliu, Silvia
    Gallego Moya, Adolfo
    Andrade, Raul J.
    Hernandez Guerra, Manuel
    Badia-Aranda, Esther
    Jimeno Mate, Carlota
    Gonzalez Santiago, Jesus
    Cuenca, Beatriz
    Bernal Monterde, Vanesa
    Delgado, Manuel
    Turnes, Juan
    Lens, Sabela
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1205 - S1206
  • [5] Glecaprevir/Pibrentasvir plus Sofosbuvir plus Ribavirin as a salvage regimen after Sofosbuvir plus Velpatasvir plus Voxilaprevir re-treatment failure
    Tergast, Tammo L.
    Kordecki, Nikolaus
    Ohlendorf, Valerie
    Beier, Christoph
    Sandmann, Lisa
    Wedemeyer, Heiner
    Cornberg, Markus
    Maasoumy, Benjamin
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (06): : 959 - 962
  • [6] Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir
    Pearlman, Brian L.
    Hinds, Andrew E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (09) : 914 - 923
  • [7] Real-World Safety and Effectiveness of Sofosbuvir/Velpatasvir/Voxilaprevir and Glecaprevir/Pibrentasvir in Hepatitis C Infected Patients
    Saxena, Varun
    Chamberland, Scott
    Hurley, Leo
    Lai, Jennifer B.
    Truong, Elizabeth
    Marcus, Julia
    Champsi, Jamila
    Hare, Brad B.
    Korn, Daniel
    Ready, Joanna B.
    Seo, Suk
    Witt, David J.
    Silverberg, Michael J.
    HEPATOLOGY, 2018, 68 : 418A - 419A
  • [8] Virological characterization of patients with chronic hepatitis C and failure to a glecaprevir/pibrentasvir or voxilaprevir/velpatasvir/sofosbuvir treatment in the international shared collaboration
    De Salazar, Adolfo
    Dietz, Julia
    Di Maio, Velia Chiara
    Fourati, Slim
    Mullhaupt, Beat
    Paolucci, Stefania
    Cabezas, Joaquin
    Stauber, Rudolf E.
    Coppola, Nicola
    Arenas, Juan
    Graf, Christiana
    Jimenez-Perez, Miguel
    Degasperi, Elisabetta
    Manuel Pascasio, Juan
    Callegaro, Maria Paola
    Vermehren, Johannes
    Rosales Zabal, Jose Miguel
    Battista Gaeta, Giovanni
    Garcia-Deltoro, Miguel
    Zoller, Heinz
    Puoti, Massimo
    Berg, Christoph
    Douglas, Mark
    Pawlotsky, Jean-Michel
    Howe, Anita
    Garcia Garcia, Federico
    Ceccherini Silberstein, Francesca
    Sarrazin, Christoph
    JOURNAL OF HEPATOLOGY, 2020, 73 : S107 - S108
  • [9] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR IN ADOLESCENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
    Bansal, Sanjay
    Pawlowska, Malgorzata
    Nebbia, Gabriela
    Di Dato, Fabiola
    Sluzewski, Wojciech
    Giacomet, Vania
    Szenborn, Leszek
    Shao, Jiang
    Yue, Mun Sang
    Hsueh, Chia-Hsiang
    Parhy, Bandita
    Gaggar, Anuj
    Kersey, Kathryn
    Mangia, Alessandra
    Kelly, Deirdre
    Indolfi, Giuseppe
    HEPATOLOGY, 2020, 72 : 571A - 571A
  • [10] Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C
    Young-A Heo
    Emma D. Deeks
    Drugs, 2018, 78 : 577 - 587
12345